Compass Therapeutics, Inc. (CMPX): Total Assets
$219.59M
As of 2025-12-31
$190.17M
As of 2026-06-30
+3.2%
3-year compound annual growth
+33.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $219.59M | +56.4% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $140.40M | -10.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $156.88M | -21.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $199.65M | +29.8% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $153.76M | +196.2% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $51.91M | n/a | 2022-03-18, Balance as of period end |
| 2020-03-31 | $3.7K | n/a | 2020-06-08, Balance as of period end |
| 2019-12-31 | $30.38M | n/a | 2021-03-05, Balance as of period end |
| 2019-03-31 | $4.9K | n/a | 2020-06-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $219.59M | +56.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare CMPX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗